<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02923414</url>
  </required_header>
  <id_info>
    <org_study_id>52187</org_study_id>
    <nct_id>NCT02923414</nct_id>
  </id_info>
  <brief_title>Comparison of High Versus Escalating Shocks in Cardioverting Atrial Fibrillation</brief_title>
  <official_title>The Efficiency and Safety of a High Energy Shock Protocol (360-360-360 J) Versus a Standard Escalating Energy Shock Protocol (125-150-200 J) in Cardioverting Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Randers Regional Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation is the most common heart rhythm disorder. For patients suffering atrial
      fibrillation direct current cardioversion is performed to reduce patients symptoms and
      prevent disease progression. The optimal energy selection for biphasic cardioversion is
      unknown.

      We aim to investigate the efficiency and safety of a high energy shock protocol (360 J)
      versus a standard escalating shock protocol (125-150-200 J) in cardioversion of atrial
      fibrillation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimal energy selection for biphasic direct current (DC) cardioversion of atrial
      fibrillation is unknown. The energy delivered should be sufficient to achieve prompt
      cardioversion but without the risk of inducing any potential injury e.g. skin burns,
      myocardial stunning or post-cardioversion arrhythmias. The use of an escalating protocol,
      with a low energy initial shock, has been considered conventional practice, originally to
      avoid post cardioversion arrhythmias when using monophasic shocks.(1) This practice has been
      directly transferred to biphasic cardioversion. The European Society of Cardiology 2016
      guidelines (2) and the American Heart Association/American College of Cardiology 2014
      guidelines on the management of atrial fibrillation (3) do not recommend any specific energy
      settings, whereas the European Resuscitation Council 2010 guidelines for cardiopulmonary
      resuscitation (4) recommend a starting energy level of 120-200 J with subsequent escalating
      energy setting.

      Previously, a non-escalating protocol (200 J) (5) has been found to have a significantly
      higher first shock success resulting in fewer shock deliveries without compromising safety
      compared with a low energy escalating shock protocol (100-150-200 J). Further, a study found
      fewer arrhythmic complications with increasing energy suggesting an 'upper limit of
      vulnerability'. It is well-established that biphasic shocks induce fewer post-shock
      arrhythmias (6), skin burns (7) and shorter periods of myocardial stunning compared with
      monophasic shocks.(8) Importantly, no correlation between increasing biphasic energy delivery
      and any complications was found in these studies. Nonetheless, the efficiency and safety of a
      high energy shock (360 J) biphasic protocol compared with a conventional low energy
      escalating protocol is unknown. Accordingly, this study aims to compare the efficiency and
      safety of a high energy protocol (360-360-360 J) versus a standard escalating protocol
      (125-150-200 J). We hypothesise that a high energy cardioversion protocol is more effective
      compared to standard escalating energy protocol, without compromising safety.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">May 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Successful cardioversion</measure>
    <time_frame>One minute following cardioversion</time_frame>
    <description>Successful cardioversion is defined as the proportion of patients in sinus rhythm one minute after cardioversion or cardioversion attempt (to a maximum of the 3 shocks in the protocol).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: First shock success</measure>
    <time_frame>Following first cardioversion attempt</time_frame>
    <description>Successful cardioversion following the first cardioversion attempt (125 J versus 360 J).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Arrhythmic events and ECG-changes following cardioversion</measure>
    <time_frame>Within four hours following cardioversion (until discharge)</time_frame>
    <description>Any post-cardioversion arrhythmias will be recorded using ECG-holtering four hours post cardioversion. Further ECG changes will be measured (sinus node dysfunction, atrioventricular delay, ventricular tachyarrhythmia or ventricular premature complexes, ST-segment deviations and recurrence of AF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Skin-discomfort, skin burns or itching</measure>
    <time_frame>Two hours after cardioversion</time_frame>
    <description>Patients self-assessment of skin discomfort and objective measurement of skin burns or itching.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Troponin I level changes following cardioversion</measure>
    <time_frame>Four hours after cardioversion</time_frame>
    <description>To evaluate changes in high sensitive cardiac troponin I levels between a baseline measurement before cardioversion and the level four hours following cardioversion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: Echocardiographic evaluation following cardioversion</measure>
    <time_frame>Two hours after cardioversion</time_frame>
    <description>Comparing a baseline echocardiographic evaluation with an evaluation performed two after cardioversion, e.g. left ventricular function using standard echocardiographic measurements.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Standard escalating shocks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to a standard escalating shock protocol using the energy settings: 125, 150, 200 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High energy shocks</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be randomized to a high energy shock protocol using the energy settings: 360, 360, 360 J. All cardioversion attempts will be performed using LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard escalating shocks</intervention_name>
    <description>125 J, 150 J, 200 J</description>
    <arm_group_label>Standard escalating shocks</arm_group_label>
    <other_name>LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>High energy shock protocol</intervention_name>
    <description>360 J, 360 J, 360 J.</description>
    <arm_group_label>High energy shocks</arm_group_label>
    <other_name>LIFEPAK 20, Physio-Control Inc., Redmond, WA, USA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt;18 years of age, scheduled for cardioversion of atrial fibrillation. Patients with
             atrial fibrillation for ≤48 hours may be cardioverted immediately. Patients with
             atrial fibrillation for &gt;48 hours will be required to have a documented weekly
             international normalized ratio (INR) ≥2.0 (including within 48 hours of cardioversion)
             or treatment with non-vitamin K oral anticoagulant for three weeks or longer.
             Alternatively, a transoesophageal echocardiogram documenting absence of intracardiac
             thrombi is accepted and cardioversion can be performed on treatment with low molecular
             weight heparin.

        Exclusion Criteria:

          -  Pregnancy, haemodynamically unstable atrial fibrillation, other arrhythmias than
             atrial fibrillation, untreated hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Løfgren, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Randers Regional Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anders S Schmidt, MB</last_name>
    <role>Principal Investigator</role>
    <affiliation>Randers Regional Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bo Løfgren, MD, PhD</last_name>
    <phone>+4578420000</phone>
    <email>bl@clin.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Randers Regional Hospital</name>
      <address>
        <city>Randers</city>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Løfgren, MD, PhD</last_name>
      <phone>+45 78420000</phone>
      <email>bl@clin.au.dk</email>
    </contact>
    <investigator>
      <last_name>Bo Løfgren, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anders S Schmidt, MB</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hans Rickers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Torp, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <reference>
    <citation>Lown B. Electrical reversion of cardiac arrhythmias. Br Heart J. 1967 Jul;29(4):469-89.</citation>
    <PMID>6029120</PMID>
  </reference>
  <reference>
    <citation>Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P; ESC Scientific Document Group . 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016 Oct 7;37(38):2893-2962. doi: 10.1093/eurheartj/ehw210. Epub 2016 Aug 27.</citation>
    <PMID>27567408</PMID>
  </reference>
  <reference>
    <citation>January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellinor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC/AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014 Dec 2;130(23):e199-267. doi: 10.1161/CIR.0000000000000041. Epub 2014 Mar 28. Erratum in: Circulation. 2014 Dec 2;130(23):e272-4.</citation>
    <PMID>24682347</PMID>
  </reference>
  <reference>
    <citation>Deakin CD, Nolan JP, Sunde K, Koster RW. European Resuscitation Council Guidelines for Resuscitation 2010 Section 3. Electrical therapies: automated external defibrillators, defibrillation, cardioversion and pacing. Resuscitation. 2010 Oct;81(10):1293-304. doi: 10.1016/j.resuscitation.2010.08.008.</citation>
    <PMID>20956050</PMID>
  </reference>
  <reference>
    <citation>Glover BM, Walsh SJ, McCann CJ, Moore MJ, Manoharan G, Dalzell GW, McAllister A, McClements B, McEneaney DJ, Trouton TG, Mathew TP, Adgey AA. Biphasic energy selection for transthoracic cardioversion of atrial fibrillation. The BEST AF Trial. Heart. 2008 Jul;94(7):884-7. Epub 2007 Jun 25.</citation>
    <PMID>17591649</PMID>
  </reference>
  <reference>
    <citation>Ambler JJ, Deakin CD. A randomized controlled trial of efficacy and ST change following use of the Welch-Allyn MRL PIC biphasic waveform versus damped sine monophasic waveform for external DC cardioversion. Resuscitation. 2006 Nov;71(2):146-51. Epub 2006 Sep 20.</citation>
    <PMID>16987583</PMID>
  </reference>
  <reference>
    <citation>Page RL, Kerber RE, Russell JK, Trouton T, Waktare J, Gallik D, Olgin JE, Ricard P, Dalzell GW, Reddy R, Lazzara R, Lee K, Carlson M, Halperin B, Bardy GH; BiCard Investigators. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol. 2002 Jun 19;39(12):1956-63.</citation>
    <PMID>12084594</PMID>
  </reference>
  <reference>
    <citation>Deakin CD, Ambler JJ. Post-shock myocardial stunning: a prospective randomised double-blind comparison of monophasic and biphasic waveforms. Resuscitation. 2006 Mar;68(3):329-33. Epub 2005 Dec 27.</citation>
    <PMID>16378672</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2016</study_first_submitted>
  <study_first_submitted_qc>October 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 4, 2016</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardioversion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

